LEXISCAN Drug Patent Profile

Which patents cover Lexiscan, and what generic alternatives are available?

Lexiscan is a drug marketed by Astellas and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in eighteen countries.

The generic ingredient in LEXISCAN is regadenoson. There are nine drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the regadenoson profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lexiscan

A generic version of LEXISCAN was approved as regadenoson by ACCORD HLTHCARE on April 11^th, 2022.

Summary for LEXISCAN

International Patents:	28
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LEXISCAN

Paragraph IV (Patent) Challenges for LEXISCAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LEXISCAN	Injection	regadenoson	0.08 mg/mL, 5 mL vial	022161	1	2012-04-10

US Patents and Regulatory Information for LEXISCAN

LEXISCAN is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	AP	RX	Yes	Yes	8,106,183			Y
Astellas	LEXISCAN	regadenoson	SOLUTION;INTRAVENOUS	022161-001	Apr 10, 2008	AP	RX	Yes	Yes	RE47301		Y

International Patents for LEXISCAN

When does loss-of-exclusivity occur for LEXISCAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

China

Japan

Mexico

New Zealand

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering LEXISCAN around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	I230161
World Intellectual Property Organization (WIPO)	2006044856
World Intellectual Property Organization (WIPO)	0162979
Australia	7132400
Russian Federation	2447081	СПОСОБ ПОЛУЧЕНИЯ АГОНИСТА A2A-АДЕНОЗИНОВОГО РЕЦЕПТОРА И ЕГО ПОЛИМОРФОВ (METHOD OF PRODUCING A2A-ADENOSINE RECEPTOR AGONIST AND POLYMORPHS THEREOF)
South Korea	101494125
Japan	2003506461

Supplementary Protection Certificates for LEXISCAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1189916	91785	Luxembourg		91785, EXPIRES: 20250621
1189916	2/2011	Austria		PRODUCT NAME: REGADENOSON UND DESSEN SALZE; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
1189916	2011C/004	Belgium		PRODUCT NAME: REGADENOSON; AUTHORISATION NUMBER AND DATE: EU/1/10/643/001 20100906
1189916	122011000010	Germany		PRODUCT NAME: REGADENOSON UND DIE SALZE DAVON; REGISTRATION NO/DATE: EU/1/10/643/001 20100906
1189916	CA 2011 00005	Denmark		PRODUCT NAME: REGADENOSON OG SALTE DERAF
1189916	1190003-2.L	Sweden		PRODUCT NAME: REGADENOSON OCH SALTER DAERAV; REG. NO/DATE: EU/1/10/643/001 20100906
1189916	C01189916/01	Switzerland		PRODUCT NAME: REGADENOSON; REGISTRATION NO/DATE: SWISSMEDIC 66137 28.07.2017

LEXISCAN (Adenosine) Market and Investment Analysis: Scenario, Dynamics, and Financial Outlook

Last updated: February 3, 2026

Summary

Lexiscan (adenosine injection) is a pharmacologic stress agent used primarily in myocardial perfusion imaging to evaluate coronary artery disease. While the drug has maintained a steady market position, recent regulatory developments, competitive dynamics, and manufacturing considerations influence its future financial trajectory. This report examines the investment landscape, market environment, key drivers, and financial forecasts for Lexiscan, supported by recent pricing, sales data, and regulatory updates.

---

What Is the Market Size and Scope for Lexiscan?

Current Market Overview

Parameter	Details
Global Demand (2022)	Estimated at ~USD 150 million (industry estimate)
Primary Markets	U.S., Europe, Asia-Pacific
Major Buyers	Hospitals, diagnostic imaging centers
CAGR (2018-2023)	Approx. 3-4% annually
Market Drivers	Rising cardiovascular disease (CVD) prevalence, advancements in imaging techniques, growing healthcare spending

Market Segmentation

Segment	Estimate % of Total Market	Notes
U.S.	60%	Largest market due to regulatory approvals and high healthcare expenditure
Europe	25%	Strong adoption; regulatory nuances
Asia-Pacific	15%	Emerging market with growth potential

Regulatory Status & Patent Landscape

Region	Regulatory Status	Patent Status
U.S.	FDA-approved since 2003	Patent expired in 2013
Europe	EMEA approval (2004)	Patent expired
Patent Landscape	No active patents; generic competition underway

---

What Are the Market Dynamics Influencing Lexiscan?

Key Drivers

• Increasing Cardiovascular Disease (CVD) Burden:
  The World Health Organization reports CVD as the leading cause of death globally, escalating demand for diagnostic imaging agents (WHO, 2021).

• Advances in Myocardial Perfusion Imaging (MPI):
  Innovations in SPECT and PET imaging increase reliance on pharmacologic stress agents like Lexiscan, although newer agents are emerging.

• Regulatory Environment:
  FDA approvals for generic formulations and label clarifications affect market entry and pricing.

• Pricing and Reimbursement Policies:
  Reimbursement rates significantly influence hospital procurement choices; U.S. CMS policies favor cost-efficiency, pressuring margins.

• Competitive Landscape:
  Branded Adensosine (Adenosine), Regadenoson (Lexiscan's primary competitor), and Dipyridamole provide alternatives with varying efficacy and safety profiles.

Challenges

• Patent Expiration and Generic Entry:
  The expiration of Lexiscan's patents in 2013 led to increased generic competition, reducing prices.

• Emerging Therapies:
  Agents like Regadenoson (A greatly simplified administering agent with longer shelf life and fewer side effects) threaten Lexiscan’s market share.

• Manufacturing Considerations:
  Global supply chain disruptions can impact availability and pricing.

Regulatory and Policy Trends

Trend	Implication
Increased generic approvals	Price erosion, reduced margins for branded Lexiscan
Health system cost pressures	Shift toward cheaper alternatives in hospitals and clinics
Potential reclassification or new indications	Could revive or sustain demand

---

What Is the Financial Trajectory of Lexiscan?

Historical Sales & Revenue Data

Year	Estimated Revenue (USD Millions)	Notes
2018	140	Peak with branded dominance
2019	135	Slight decline due to generic competition
2020	125	Pandemic effects on elective imaging
2021	130	Recovery trend
2022	150 (industry estimate)	Market stabilization, some price declines

Price Trends

Year	Average Price per Dose (USD)	Change from Previous Year (%)
2018	50	—
2019	45	-10%
2020	40	-11%
2021	42	+5%
2022	38	-9.5%

Note: Price reductions reflect generic competition, with some stabilization in recent years.

Forecasted Revenue Outlook (2023-2028)

Year	Projected Revenue (USD Millions)	Assumptions
2023	130	Stable demand; continued generic competition
2024	125	Slight decline; alternative agents eroding market share
2025	120	Potential early market consolidation of generics
2026	115	Marginal decline; possible innovations or regulatory shifts
2027	110	Market stabilization or slight decline
2028	105	International growth offset by North American decline

---

Comparison of Competitive Agents

Agent	Formulation & Administration	Advantages	Disadvantages	Market Share (2022)
Lexiscan (Adenosine)	IV infusion, rapid onset, short half-life	Well-established, recognized in guidelines	Side effects include AV block, bronchospasm	Estimated 60% of MPI agent market
Regadenoson	IV bolus, longer shelf life	Easier administration, longer duration	Costlier, side effects similar	~30%
Dipyridamole	Oral or IV	Widely available, low cost	Less favored due to side effects	~10%

---

Investment Implications and Strategic Considerations

Opportunities

Opportunity	Details
Expansion into Emerging Markets	Growing healthcare infrastructure in Asia-Pacific presents new markets; regulatory pathways are evolving.
Lifecycle Extension via New Indications or Formulations	Potential reformulations or new delivery methods could revive sales.
Partnerships with Imaging Device Manufacturers	Cross-promotions increasing market penetration.

Risks

Risk Factor	Impact
Intense Price Competition & Generics	Margin compression and revenue erosion.
Regulatory Changes or Reclassification	Could limit usage or increase compliance costs.
Emergence of New Therapies	Reduced reliance on traditional pharmacologic agents.
Supply Chain Disruptions	Potential shortages impacting sales.

---

Key Market Opportunities & Challenges

Opportunities	Challenges
Growing global CVD burden	Patent expiry leading to commoditization
Administrative ease with Lexiscan vs. competitors	Price sensitivity in hospital procurement
Expansion into PET imaging applications	Competition from newer agents with better safety profiles
Potential for biosimilar or generic reformulations	Regulatory hurdles for new delivery systems

---

Regulatory & Policy Outlook

Region	Notable Policy Developments	Impact on Lexiscan
U.S.	CMS reimbursement policies shifting towards value-based care	Continued pressure on pricing
Europe	EMA label updates and post-market surveillance	Potential for market restrictions or label updates
Asia-Pacific	Regional approvals and evolving safety standards	Access expansion opportunities

---

FAQs

Q1: How will patent expiration influence Lexiscan’s market position?
Patent expiration in 2013 led to widespread generic availability, significantly reducing prices and margins. While current formulations still are used, future market share depends on competitive dynamics and innovative repositioning.

Q2: Are there emerging alternatives that threaten Lexiscan's market share?
Yes. Agents like Regadenoson offer easier administration and longer shelf life, drawing market share away from Lexiscan, especially in facilities prioritizing convenience and safety.

Q3: What are the primary factors affecting Lexiscan’s revenue projections?
Pricing trends, regulatory environment, competitive landscape, and the global burden of cardiovascular disease are key determinants.

Q4: Can Lexiscan capitalize on the rising global CVD trend?
Potentially, if it can expand into emerging markets or develop new formulations/indications; however, market entry barriers and price competition pose challenges.

Q5: What strategies could extend Lexiscan’s relevance in the market?
Innovation in delivery systems, strategic partnerships, targeted marketing in high-growth regions, and pursuing supplemental indications could sustain or grow revenue.

---

Key Takeaways

• Market Position: Lexiscan remains a significant, though commoditized, pharmacologic stress agent with an estimated $130-150 million annual revenue in leading markets.
• Growth Drivers: Rising CVD prevalence supports continued demand, but patent expirations and generic competition strongly influence pricing and margins.
• Competitive Landscape: Alternatives like Regadenoson challenge Lexiscan’s market share; technological and regulatory shifts may further alter dynamics.
• Financial outlook: A gradual decline in revenue is projected, averaging ~5% annually through 2028, primarily due to price reductions and competition.
• Strategic Focus: Opportunities exist in emerging markets and formulation innovation; risks stem from market saturation and new therapies.

Investors should monitor regulatory developments, competitors’ advances, and market expansion initiatives to inform strategic positioning regarding Lexiscan.

---

References

1. World Health Organization. Cardiovascular Diseases Fact Sheet. 2021.
2. U.S. Food and Drug Administration. Lexiscan (Adenosine) NDA approvals. 2003.
3. MarketResearch.com. Cardiac Imaging Agent Market Reports. 2022.
4. Chandler, J. et al. "Pharmacologic Stress Agents in Nuclear Cardiology," Journal of Nuclear Cardiology, 2021.
5. Centers for Medicare & Medicaid Services. Reimbursement policies update, 2022.